Inventiva Pharma
Daix
About Inventiva Pharma
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $488.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: epa:IVA
- Website: inventivapharma.com
- Phone: +33 (0)3 80 44 75 00
Industries & Categories
Biopharma, Biotechnology, Clinical Trials, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/inventiva-pharma-50895 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.